Pegylated Interferon Alfa-2b and Nilotinib for Augmentation of Complete Molecular Response in Chronic Myeloid Leukaemia

NCT02001818 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Chronic Myeloid Leukaemia

Interventions

DRUG: Nilotinib, Pegylated interferon alpha-2b, Imatinib

Sponsor

Australasian Leukaemia and Lymphoma Group

Collaborators

[object Object]
[object Object]